Table 1. Patient characteristics, clinical response, and toxicity
Patient Age/sex Disease sites Prior therapy No. of cycles received* Response (mos.) Toxicity (grade III/IV)
1 52/M Lung I, S 2 PR (15+) Enterocolitis; dermatitis
2 40/F Supraclavicular lymph node C, I, S 1 NR Dermatitis; vitiligo
3 39/M Lung, mediastinum, subcutaneous S 6 NR (mixed)
4 55/F Skin, subcutaneous I, S 1 NR Pulmonary infiltrates
5 67/M Liver, retroperitoneum, subcutaneous C, I, R, S 4 NR ANA+
6 59/M Lung, subcutaneous I, S 4 NR Vitiligo
7 48/M Lung, brain, adrenal, subcutaneous I, S 2 NR
8 48/M Lung, liver, adrenal, mesentery, subcutaneous C, I, S 2 NR
9 53/M Mediastinum, mesentery, skin I, R, S 2 NR Colitis
10 62/M Lung, hilum C, I, S 2 NR (mixed)
11 54/M Lung, brain, subcutaneous C, S 5 CR (12+) Hypophysitis
12 43/M Subdiaphragm, muscle, subcutaneous I, S 3 NR Hepatitis; ANA+
13 49/F Lung, subcutaneous C, I, S 4 CR (11+) Dermatitis
14 63/M Lung, pelvic lymph node S 4 NR
  • ANA, antinuclear Ab; C, chemotherapy; CR, complete response; F, female; I, immunotherapy; M, male; NR, no response; PR, partial response; R, radiotherapy; S, surgery

  • * One treatment cycle consists of one infusion of anti-CTLA-4 Ab and one vaccination with gp 100:209-217(210M) and gp 100:280-288(288V) peptides

  • Grade I/II toxicity